The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is associated with high clinical and economic burden. Optimal pharmacological therapy for COPD aims to reduce symptoms and the frequency and severity of exacerbations. Umeclidinium/vilanterol (UMEC/VI) is an approved combination therapy for on...

Descripción completa

Detalles Bibliográficos
Autores principales: Buikema, Ami R., Brekke, Lee, Anderson, Amy, Koep, Eleena, Van Voorhis, Damon, Sharpsten, Lucie, Hahn, Beth, Ray, Riju, Stanford, Richard H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180385/
https://www.ncbi.nlm.nih.gov/pubmed/30338068
http://dx.doi.org/10.1186/s40248-018-0151-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180385/
https://www.ncbi.nlm.nih.gov/pubmed/30338068
http://dx.doi.org/10.1186/s40248-018-0151-6

Ejemplares similares